Skip to main content
AB

Acenxion Biosystems

Acenxion Biosystems develops an automated phenotypic antimicrobial susceptibility testing (AST) system that delivers results in 4-6 hours, significantly reducing the time required for effective antibiotic treatment. This technology addresses the critical issue of delayed test results, which can lead to increased antibiotic resistance and poor patient outcomes.

Lawrence, United StatesFounded 202011200+ followers
Updated 4 months ago

Funding

$1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Current phenotypic antimicrobial susceptibility testing (AST) methods are labor-intensive and can take days to produce results. This delay can lead to the prescription of broad-spectrum antibiotics or ineffective treatments, increasing antibiotic resistance and negatively impacting patient outcomes.

Solution

Acenxion Biosystems offers an automated phenotypic AST system that delivers results in 4-6 hours, significantly reducing the time required for targeted antibiotic treatment. The system is designed to seamlessly integrate into existing clinical workflows, enabling clinicians to rapidly identify effective treatments and minimize unnecessary antibiotic exposure. By providing faster and more accurate AST results, Acenxion aims to improve antibiotic stewardship, reduce the spread of antimicrobial resistance (AMR), and enhance patient care. The technology combines pathogen attributes with novel technology to deliver accurate results quickly.

Target Audience

The primary customers are public health laboratories, hospitals and clinics, and healthcare professionals who require rapid and accurate antimicrobial susceptibility testing.

Features

  • Automated phenotypic AST system providing results in 4-6 hours
  • Scalable design for seamless integration into current clinical workflows
  • Enables rapid use of targeted treatments, minimizing antibiotic exposure
  • Supports improved antibiotic stewardship and reduces the spread of AMR
  • Cost-effective medical device technology
This profile is AI-generated and may contain inaccuracies.